(Total Views: 186)
Posted On: 08/25/2017 1:54:01 PM
Post# of 72447
There is no proper future valuation anymore. Very rare.
I actually derisked ARTH a bit today on the pop, still may continue higher (.94 resistance). I see no problem getting their 510k, though there also could be some questions to answer. If it dips back I'll be reloading. Arch isn't without competition and will need to penetrate the markets. They get the 510, partner is very likely.
Ipharma clears the next quarter with results that meet/exceed endpoints?
Sky is the limit.
I actually derisked ARTH a bit today on the pop, still may continue higher (.94 resistance). I see no problem getting their 510k, though there also could be some questions to answer. If it dips back I'll be reloading. Arch isn't without competition and will need to penetrate the markets. They get the 510, partner is very likely.
Ipharma clears the next quarter with results that meet/exceed endpoints?
Sky is the limit.
(0)
(0)
